JPWO2020241749A1 - - Google Patents
Info
- Publication number
- JPWO2020241749A1 JPWO2020241749A1 JP2021522856A JP2021522856A JPWO2020241749A1 JP WO2020241749 A1 JPWO2020241749 A1 JP WO2020241749A1 JP 2021522856 A JP2021522856 A JP 2021522856A JP 2021522856 A JP2021522856 A JP 2021522856A JP WO2020241749 A1 JPWO2020241749 A1 JP WO2020241749A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019100136 | 2019-05-29 | ||
JP2019100136 | 2019-05-29 | ||
PCT/JP2020/021108 WO2020241749A1 (ja) | 2019-05-29 | 2020-05-28 | スルホンアミド化合物と免疫調節剤を用いるがん併用療法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2020241749A1 true JPWO2020241749A1 (ja) | 2020-12-03 |
JP7179174B2 JP7179174B2 (ja) | 2022-11-28 |
Family
ID=73553795
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021522856A Active JP7179174B2 (ja) | 2019-05-29 | 2020-05-28 | スルホンアミド化合物と免疫調節剤を用いるがん併用療法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20220226291A1 (ja) |
EP (1) | EP3978017A4 (ja) |
JP (1) | JP7179174B2 (ja) |
KR (1) | KR20220015430A (ja) |
AU (1) | AU2020283299A1 (ja) |
MA (1) | MA56065A (ja) |
TW (1) | TWI781405B (ja) |
WO (1) | WO2020241749A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4301735A1 (en) * | 2021-03-02 | 2024-01-10 | Boundless Bio, Inc. | Ribonucleotide reductase (rnr) inhibitors and uses thereof |
WO2023043938A1 (en) * | 2021-09-17 | 2023-03-23 | Boundless Bio, Inc. | Sulfamide ribonucleotide reductase (rnr) inhibitors and uses thereof |
WO2023043923A1 (en) * | 2021-09-17 | 2023-03-23 | Boundless Bio, Inc. | Cyclic sulfonamide ribonucleotide reductase (rnr) inhibitors and uses thereof |
WO2024059563A1 (en) * | 2022-09-13 | 2024-03-21 | Boundless Bio, Inc. | Cyclic sulfonamide ribonucleotide reductase (rnr) inhibitors and uses thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004004771A1 (ja) * | 2002-07-03 | 2004-01-15 | Ono Pharmaceutical Co., Ltd. | 免疫賦活組成物 |
WO2017209155A1 (ja) * | 2016-05-31 | 2017-12-07 | 大鵬薬品工業株式会社 | スルホンアミド化合物又はその塩 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2015203324B2 (en) * | 2009-07-20 | 2016-07-28 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
JOP20200096A1 (ar) * | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
PT3116909T (pt) * | 2014-03-14 | 2020-01-30 | Novartis Ag | Moléculas de anticorpos para lag-3 e suas utilizações |
JP7023690B2 (ja) | 2017-12-06 | 2022-02-22 | 株式会社東芝 | 道路維持管理システム、道路維持管理方法及びコンピュータプログラム |
-
2020
- 2020-05-28 WO PCT/JP2020/021108 patent/WO2020241749A1/ja unknown
- 2020-05-28 JP JP2021522856A patent/JP7179174B2/ja active Active
- 2020-05-28 KR KR1020217042364A patent/KR20220015430A/ko not_active Application Discontinuation
- 2020-05-28 US US17/614,074 patent/US20220226291A1/en active Pending
- 2020-05-28 TW TW109117778A patent/TWI781405B/zh active
- 2020-05-28 EP EP20814485.7A patent/EP3978017A4/en active Pending
- 2020-05-28 MA MA056065A patent/MA56065A/fr unknown
- 2020-05-28 AU AU2020283299A patent/AU2020283299A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004004771A1 (ja) * | 2002-07-03 | 2004-01-15 | Ono Pharmaceutical Co., Ltd. | 免疫賦活組成物 |
WO2017209155A1 (ja) * | 2016-05-31 | 2017-12-07 | 大鵬薬品工業株式会社 | スルホンアミド化合物又はその塩 |
Also Published As
Publication number | Publication date |
---|---|
JP7179174B2 (ja) | 2022-11-28 |
WO2020241749A1 (ja) | 2020-12-03 |
MA56065A (fr) | 2022-04-06 |
TW202110442A (zh) | 2021-03-16 |
KR20220015430A (ko) | 2022-02-08 |
EP3978017A1 (en) | 2022-04-06 |
TWI781405B (zh) | 2022-10-21 |
EP3978017A4 (en) | 2023-06-28 |
AU2020283299A1 (en) | 2022-02-03 |
US20220226291A1 (en) | 2022-07-21 |
Similar Documents
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210914 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210914 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220823 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221003 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20221025 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20221115 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7179174 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |